Clinical Study | Office of Clinical Research

Phase 1, Two-Part, Multicenter, Non-Randomized, Open-Label, Multiple Dose First-In-Human Study Of Ds-8201A, In Patients With Advanced Solid Malignant

Posted Date: May 15, 2019

Investigator: Trisha Wise-Draper
Type of Study: Drug

The main purpose of this study is to Test the safety of a study drug called DS-8201a and see what effects (good and bad) it has on you and your cancer. DS-8201a targets a protein called human epidermal growth factor receptor 2 (HER2) which is found on the surface of cancer cells in large amounts. DS

Criteria:

To Be Eligible To Participate In This Study, Patients Must Have Her2 Positive Breast Cancer, Her2 Po

Keywords:

Breast, Cancer, Ds8201-A-J101, Gastrointestinal, Phase I

For More Information:

Billie Boaz
(513) 584-7698
kastla@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List